Singapore, April 28 -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and SpringWorks Therapeutics, Inc., a US-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks.

The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) based on SpringWorks' cash balance as of December 31, 2024, and a premium of 26% to SpringWorks' unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction betw...